Market closed

Exelixis/$EXEL

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Exelixis

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Ticker

$EXEL

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Alameda, United States

Employees

1,310

Website

www.exelixis.com

Exelixis Metrics

BasicAdvanced

$10B

23.03 $1.55

0.54 -

Price and volume

Market cap

$10B

Beta

0.54

52-week high

$36.45

52-week low

$20.02

Average daily volume

2.1M

Financial strength

Current ratio

3.93

Quick ratio

3.732

Long term debt to equity

8.545

Total debt to equity

8.545

Management effectiveness

Return on assets (TTM)

12.81%

Return on equity (TTM)

20.20%

Valuation

Price to earnings (TTM)

23.033

Price to revenue (TTM)

5.07

Price to book

4.48

Price to tangible book (TTM)

4.61

Price to free cash flow (TTM)

26.061

Growth

Revenue change (TTM)

17.31%

Earnings per share change (TTM)

441.02%

3-year revenue growth (CAGR)

18.41%

3-year earnings per share growth (CAGR)

44.75%

What the Analysts think about Exelixis

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Exelixis stock.

Exelixis Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Exelixis Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Exelixis News

AllArticlesVideos

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Business Wire·2 days ago

The Best Defensive Stocks To Hedge Against Market Uncertainty

Seeking Alpha·4 days ago

Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza

Seeking Alpha·5 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EXEL

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Exelixis stock?

Exelixis (EXEL) has a market cap of $10B as of January 15, 2025.

What is the P/E ratio for Exelixis stock?

The price to earnings (P/E) ratio for Exelixis (EXEL) stock is 23.03 as of January 15, 2025.

Does Exelixis stock pay dividends?

No, Exelixis (EXEL) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Exelixis dividend payment date?

Exelixis (EXEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Exelixis?

Exelixis (EXEL) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.